...president and CEO Allan Jones also announced plans to step down this year.Musculoskeletal disease company Dyne Therapeutics Inc....

...lymphoma 6 DMPK – Dystrophia myotonica-protein kinaseSARS-CoV-2 S – SARS-CoV-2 spike protein TFRC (TFR) (CD71) – Transferrin receptor Danielle Golovin Dyne Therapeutics Inc. University...

...the same tissue-targeting goal as the antibody-oligonucleotide conjugates developed by Avidity Biosciences Inc. (NASDAQ:RNA) and Dyne Therapeutics Inc....
...product than typical antibody conjugation methods.TARGETSTNC (TN) – Tenascin C Karen Tkach Tuzman Ionis Pharmaceuticals Inc. Aro Biotherapeutics Co. Dyne Therapeutics Inc. Avidity...

...in which two other biopharmas went public, with one gaining and the other ceding value. Dyne Therapeutics Inc....

...upsized offering; its aftermarket gains of $4.90 to $23.90 lifted its valuation to nearly $1 billion.Dyne Therapeutics Inc....
...joined the IPO queue in September alone, including preclinical exosome therapeutics company Codiak Biosciences Inc. Virginia Li IPO Dyne Therapeutics Inc....

...industry. Dyne, Silence join NASDAQ queueTwo weeks after raising $115 million in a crossover-heavy series B round, Dyne Therapeutics Inc....
...Myers Squibb Co. Forbius Takeda Pharmaceutical Co. Ltd. Blackstone Group Bio-Thera Solutions Ltd. BeiGene Ltd. Prelude Therapeutics Inc. Silence Therapeutics plc Sirnaomics Inc. RNAimmune Inc. Dyne Therapeutics Inc. ReViral...

...succeeds Lesley Stolz, who stepped down as EVP and CBO in November. Muscle diseases company Dyne Therapeutics Inc....
...NASDAQ:VIR), Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) and Sangamo Therapeutics Inc. (NASDAQ:SGMO). Robin Sawka, BioCentury Staff Blackstone Group Ribometrix Inc. Dyne Therapeutics Inc. Annexon...

...chief development officer. She was SVP and head of regulatory affairs at Novartis’ oncology unit. Dyne Therapeutics Inc....
...was VP of clinical development at Flexion Therapeutics (NASDAQ:FLXN). Hongjiang Li and Elizabeth S. Eaton, Staff Writers Dyne Therapeutics Inc. Imara...

...at Pierre Fabre Group and SVP of the Pierre Fabre innovation fund. Muscle disease company Dyne Therapeutics Inc....
...$150M Fund” ). BioCentury Staff Vertex Pharmaceuticals Inc. Nektar Therapeutics Sangamo Therapeutics Inc. Neurocrine Biosciences Inc. Neovacs S.A. Ascletis Pharmaceuticals Co. Ltd. 4BIO Capital Dyne Therapeutics Inc. Avidity...

...Karen Brown as SVP, intellectual property and legal affairs. Stehman-Breen was CMO of Atlas Venture-backed Dyne Therapeutics Inc....